How Unfair Is the Coin?
The author reflects on their journey with Reverie Labs, a startup acquired by Ginkgo Bioworks. They discuss the challenges of selling software to pharmaceutical companies and the evolution of their business model. The article highlights the complexities of the pharmaceutical industry's procurement processes and the transition from software to drug development.
- ▪Reverie Labs was co-founded in 2017 and acquired by Ginkgo Bioworks in February 2024.
- ▪The company transitioned from a software-driven model to developing its own drug assets using machine learning technology.
- ▪Selling software to pharmaceutical companies proved challenging due to their limited procurement of external software.
Opening excerpt (first ~120 words) tap to expand
I’m reviving my blog after some time away — it’s been an eventful 12 months. In February 2024, Reverie Labs, the startup I co-founded in 2017, was acquired by Ginkgo Bioworks. I’m now on leave from Ginkgo and I’ve joined Y Combinator as a Visiting Partner, giving me the chance to work with the next generation of companies. Especially in this new role, I’ve been thinking a bit about what worked, what didn’t work, and what lessons I can take forward. We had quite the journey – 6+ years of building at the intersection of AI and drug discovery.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Ankitg.
Discussion
0 commentsMore from Ankitg
